Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

Find Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Near You

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses With Placebo as Treatment for Rhinovirus (RV) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Status: Recruiting
Location: See all (14) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 85
Healthy Volunteers: f
View:

⁃ Sign informed consent for study participation and medical records release (if needed). Male or female age ≥40 years and ≤85 years at the time of signing the informed consent at Screening.

⁃ If sexually active and/or of child-bearing potential (both females and males), must agree to use a highly effective form of contraception at the time of randomization until 30 days (females) or 90 days (males) after the last dose. Female participants may not use hormonal birth control as a sole method. Participants will be asked to commit to this criterion at screening even though it does not need to be implemented until treatment is received.

⁃ Confirmed diagnosis of COPD, defined as chronic cough, sputum production, and/or dyspnea with airflow obstruction which is not fully reversible (that is, post bronchodilator FEV1/FVC ratio \<0.70 and post bronchodilator FEV1 ≥20% and \<80% of predicted normal value).

⁃ History of AECOPD with at least 1 documented AECOPD within 1 year of Screening. AECOPD is defined as an event characterized by dyspnea and/or cough and increased sputum purulence/change in sputum color that worsens over several days, and requires at least one of the following for 2 days

• Increase frequency or dose of beta agonist(s), oxygen, breathing treatments or chronic COPD medications (Mild Exacerbation)

• Use of oral or systemic steroids (Moderate Exacerbation), or

• Use of Antibiotics (Moderate Exacerbation), or

• Emergency room visit or hospitalization (Severe Exacerbation).

⁃ CAT score ≥10 at screening.

⁃ Able to comply with all study requirements, including the use of a mobile application to complete daily PROs, perform nasal swabs at home, and able to assess when they have cold symptoms.

⁃ Interacts with people at least twice a week without a mask (e.g., grocery shopping, dinner with grandchildren, eating at a restaurant, going to the movies, etc.) or are living in a multigenerational home.

Locations
United States
Arizona
AMR Clinical - Tempe
RECRUITING
Tempe
California
NewportNativeMD, Inc.
RECRUITING
Newport Beach
Apex Clinical Research
RECRUITING
San Diego
Florida
VM Clintrials
RECRUITING
Miami Lakes
Georgia
Accelerated Clinical Trials, LLC
RECRUITING
Snellville
Indiana
Velocity Clinical Research - Valparaiso
RECRUITING
Valparaiso
Maryland
Patient First Clinical Trials (PFCTRIALS)
RECRUITING
Lutherville
North Carolina
CRC Kings Mountain
RECRUITING
Kings Mountain
New York
Brooklyn Clinical Research
RECRUITING
Brooklyn
Ohio
Remington-Davis, Inc.
RECRUITING
Columbus
Pennsylvania
Clinical Research Associates of Central PA, LLC
RECRUITING
Dubois
Preferred Primary Care Physicians - St. Clair
RECRUITING
Pittsburgh
South Carolina
Velocity Clinical Research - Anderson
RECRUITING
Anderson
Clinical Research of Rock Hill
RECRUITING
Rock Hill
Contact Information
Primary
Karen Fusaro
kfusaro@altesa.com
610-242-0903
Time Frame
Start Date: 2026-05-01
Estimated Completion Date: 2027-11-15
Participants
Target number of participants: 180
Treatments
Experimental: Dosing Group 1 VPV 1000 mg
The first dose of 1,000 mg VPV will be taken at the study site with food once the Day 1 visit is completed. The second dose of 1,000 mg VPV will be taken at home the following morning with food. The subsequent 1,000 mg doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses.
Experimental: Dosing Group 2 VPV 500 mg
The first dose of 1,000 mg VPV will be taken at the study site with food once the Day 1 visit is completed. The second dose of 500 mg VPV will be taken at home the following morning with food. The subsequent 500 mg doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses.
Placebo_comparator: Dosing Group 3 Placebo
The first dose of placebo will be taken at the study site with food once the Day 1 visit is completed. The second dose of placebo will be taken at home the following morning with food. The subsequent placebo doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses
Sponsors
Leads: Altesa Biosciences, Inc.

This content was sourced from clinicaltrials.gov